It has been described that patients with type 2 diabetes have elevated levels of circulating FAP compared with nondiabetic subjects, thus suggesting that insulin resistance led to an inactivation of FGF21 and to the attenuation of its beneficial effects [90,169]. The gene discussed is FAP; the disease is type 2 diabetes mellitus.